A post hoc analysis was also done to determine change from baseline in the EF domain score for each baseline ED severity subgroup. Safety was assessed by evaluating all reported treatment-emergent adverse events, vital signs measurements, electrocardiograms, and standard safety laboratory assessments for all randomized patients. Treatment-emergent adverse events were defined as any adverse event that first occurred or worsened after randomization, and were mapped with the Medical Dictionary for Regulatory Activities.
This medication is not typically used in women. However, if you are pregnant, planning to become pregnant, or breastfeeding, discuss with your healthcare provider before taking this medication. Store this medication at room temperature, away from heat, light, and moisture. Keep out of reach of children and pets. If you suspect an overdose, seek immediate medical attention or call your local poison control center.
Symptoms of overdose may include severe dizziness, fainting, or an erection that lasts longer than 4 hours. Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.No compounded medications are reviewed by the FDA for safety or efficacy. No compounded medications are reviewed by the FDA for safety or efficacy. Subjects voluntarily reported adverse events throughout the study.
A sample size of 250 patients would give approximately 90% power to detect a significant treatment effect between placebo and the least-effective tadalafil dosing group.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 5mg | 270 + 10 Pills | 205.81€ 196.01€ | |
| Cialis Generic | 20mg | 270 + 10 Pills | 335.21€ 319.25€ | |
| Cialis Generic | 2.5mg | 360 + 10 Pills | 260.03€ 247.65€ | |
| Tadalista Super Active | 20mg | 60 + 8 Pills | 230.32€ 219.35€ | |
| Cialis Generic | 5mg | 90 + 6 Pills | 115.91€ 110.39€ | |
| Cialis Generic | 5mg | 10 Pills | 29.39€ 27.99€ | |
| Cialis Generic | 60mg | 30 + 2 Pills | 85.33€ 81.27€ | |
| Cialis Generic | 10mg | 10 Pills | 31.41€ 29.91€ | |
| Cialis Generic | 60mg | 90 + 6 Pills | 196.67€ 187.30€ | |
| Cialis Generic | 2.5mg | 180 + 10 Pills | 154.86€ 147.49€ |
All analyses were conducted on an intent-to-treat basis.
The ability of a drug to reach steady state results from the frequency of administration relative to half-life. The 17.5-hour half-life of tadalafil makes it an ideal candidate for once daily therapy because steady-state plasma concentrations are attained within five days of daily dosing, and exposure is approximately 1.6-fold greater than after a single dose [11]. If 5-mg and 10-mg doses are taken daily, a cumulative tadalafil plasma exposure equivalent to on-demand doses of 8mg and 16mg, respectively, could be achieved in a few days. Once-a-day dosing and every-other-day day dosing with tadalafil have been compared with on-demand dosing. In one study, 72% of men preferred once-a-day dosing [12], and in another, 42% preferred every-other-day dosing [13].
Neither study compared the efficacy and safety of scheduled dosing with placebo. Thus, the purpose of the current study was to assess the efficacy and safety of once-a-day dosing of tadalafil 5 and 10mg versus placebo as a new treatment regimen for ED. Patients ≥18 years of age, in a monogamous relationship with a female partner, who reported ≥three-month history of ED could be enrolled. Patients and partners had to sign informed consent and agree not to use other ED treatments during the study. Written informed consent was obtained in conformity with the Declaration of Helsinki (revised 1989) and applicable local laws. Efficacy analyses included all randomized patients who had a baseline measurement and at least one post-baseline measurement.
The last observation carried forward imputation methodology was used to replace missing IIEF EF domain scores.
| Aspect | Details | Notes |
|---|---|---|
| Active Ingredient | Tadalafil | Dose: 10mg |
| Drug Class | Phosphodiesterase Inhibitor | Used for erectile dysfunction |
| Typical Onset | 30-60 minutes | Varies among individuals |
| Duration of Effect | Up to 36 hours | Long-lasting effect |
For each SEP question, baseline and post-baseline scores were the number of “yes” responses relative to the number of sexual encounters during the run-in and treatment periods, respectively. Proportions of “yes” responses to SEP diary questions were treated as continuous variables.
The ethics committees of all participating institutions approved the final protocol. Subjects were excluded from enrollment for any of the following: ED caused by other sexual or endocrine disorders such as premature ejaculation or hypogonadism, history of radical prostatectomy (except bilateral nerve-sparing prostatectomy) or other pelvic surgery with subsequent ED, clinically significant hepatobiliary or renal disease, hemoglobin A1c >13%, unstable cardiovascular disease [14], current nitrate use, congestive heart failure, or recent significant central nervous system injuries. Patients who had previously enrolled in any tadalafil study, and those with prior ineffective treatment with tadalafil 60mg uk sildenafil were ineligible. This multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluated the efficacy and safety of once-a-day dosing of placebo, tadalafil 5mg, and tadalafil 10mg, administered for 12 weeks to men with ED from 20 centers from Argentina, Brazil, France, Germany, and the United Kingdom. This study (Lilly ICOS LLC study identifier H6-MC-LVCV) began with a screening period that lasted four to five weeks.
Eligible subjects were randomly assigned via central telephone to treatment groups 1:2:2 (placebo:5mg, tadalafil:10mg, tadalafil). Randomization was stratified by ED severity as measured by the International Index of Erectile Function Erectile Function domain (IIEF EF) [15]. Three stratifications of severity were used: severe (EF domain score 1–10), moderate (11–16), and mild (17–30). Because patients were enrolled based on a history of ED, some men scored 26–30 (“no ED”) [15] at baseline. The protocol stipulated that these men would be included in the mild category. IIEF EF domain, SEP2, and SEP3 were analyzed with an Analysis of Covariance model that included terms of treatment group, pooled site, baseline value for each primary efficacy variable, and baseline-by-treatment interaction (if p<0.10).
aPrivate Practice of Urology and Andrology, Hamburg, Germany bNeuro-Urology Unit, Department of Neurological Rehabilitation, AP-HP, Raymond Poincaré Hospital, Garches, France eInstituto Médico Especializado (IME), Buenos Aires, Argentina Accepted February 21, 2006; Published online March 21, 2006 DOI: 10.1016/j.eururo.2006.02.052 External LinkAlso available on ScienceDirect External Link Medical management of erectile dysfunction (ED) changed with the observation in 1992 that the nitric oxide-cyclic GMP pathway plays a critical role in erectile function (EF) and defects in this pathway may cause some forms of ED [1]. This observation motivated the development of oral inhibitors of phosphodiesterase 5 for this indication: sildenafil citrate (sildenafil), tadalafil, and vardenafil HCl (vardenafil) [2–4]. Before oral agents were introduced, pharmacological ED treatment was limited tadalafil for premature ejaculation to penile injections or intraurethral insertion of vasoactive drugs or prostaglandin E1. Although PDE5 inhibitor pharmacotherapy is less invasive and easier to use, sexual activity remains temporally linked to treatment. For all three PDE5 inhibitors, men must take medication on demand before sexual activity [5–7].
Planning sexual activity around taking a pill is burdensome to some patients and their partners [8]. The mean half-life of sildenafil and vardenafil is about four hours [5,6]; the mean half-life of tadalafil is 17.5hours [7]. Tadalafil 10 or 20mg taken on demand is well tolerated and efficacious for up to 36hours in clinical studies [9,10]. This duration may permit men with ED and their partners to disconnect sexual activity from dosing. Historically, tadalafil has been taken on demand at doses of 10 or 20mg. To protect against type 1 error caused by comparing two tadalafil doses with placebo, the pairwise p-values that compared treatment groups were adjusted by the method of Dunnett [16].
A logistic regression model that included terms of pooled site, treatment group, EF at baseline, and baseline-by-treatment interaction was used to perform secondary analysis to evaluate GAQ at endpoint by treatment group.
The slow dissolution in the mouth allows for targeted local or systemic effects, potentially enhancing the efficacy of the medication. As with any medication, side effects can occur. Common side effects may include headache, flushing, upset stomach, abnormal vision, and muscle pain. If you experience any severe or persistent side effects, contact your healthcare provider immediately. Yes, this medication can be taken with or without food.
However, it is recommended to avoid consuming high-fat meals as they may delay the absorption of the medication. If you miss a dose, take it as soon as you remember. If it is close to the time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take two doses at the same time. It is generally recommended to avoid alcohol while taking this medication as it may increase the risk of side effects such as dizziness and lightheadedness. Only patients who responded to GAQ were included in the analysis.
Treatment lasted 12 to 15 weeks and consisted of three visits four to five weeks apart. Patients were instructed to take one dose of study drug around the same time each day. Three efficacy instruments were used: the IIEF EF domain, the Sexual Encounter Profile (SEP) diary, and a Global Assessment Question (GAQ): “Has the treatment you have been taking during this study improved your erections?”. The co-primary efficacy measures were change from baseline in IIEF EF domain score, and change from baseline in per-patient mean percentage of “yes” responses to SEP Question 2 (SEP2, “Were you able to insert your penis into your partner’s vagina?”) and SEP Question 3 (SEP3, “Did your erection last long enough for you to have successful intercourse?”). Secondary efficacy measures were percentage of “yes” responses to the GAQ; and percentage of men who achieved an EF domain score of at least 26 (“no ED”) at endpoint, who had a baseline EF domain score below 26. The percentage of patients who attained an IIEF EF score of 26–30 at endpoint was analyzed with a logistic model that included terms of pooled site, treatment group, EF at baseline, and baseline-by-treatment interaction (if p<0.10).